VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

P. aeruginosa DNA Vaccine encoding OprF P. aeruginosa DNA vaccine pGACAG-OprF/OprI P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA P. aeruginosa DNA vaccine pGACAG-PcrV P. aeruginosa OprI Protein Vaccine P. aeruginosa PcrV Protein Vaccine SL3261-P. aeruginosa serogroup O11 O antigen
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004189
  • Type: DNA vaccine
  • Status: Research
  • Antigen: The pVR1020/oprF plasmid.
  • OprF gene engineering:
    • Type: DNA vaccine construction
    • Description: The 977-bp oprF gene was cloned from P. aeruginosa PAO1 genomic DNA into the eukaryotic expression plasmid pVR1020 (Price et al., 2001).
    • Detailed Gene Information: Click Here.
  • Vector: pVR1020
  • Immunization Route: abdomen gene gun
  • Vaccine Ontology ID: VO_0004570
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • OprF gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • OprI gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pGACAG (Saha et al., 2006)
  • Immunization Route: intramuscular electroporation
  • Vaccine Ontology ID: VO_0004572
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • OprF gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • OprI gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • PcrV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • pilA gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pGACAG (Saha et al., 2006)
  • Immunization Route: intramuscular electroporation
  • Vaccine Ontology ID: VO_0004571
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • PcrV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pGACAG (Saha et al., 2006)
  • Immunization Route: intramuscular electroporation
  • Vaccine Ontology ID: VO_0004190
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant OprI protein
  • OprI gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: aluminum hydroxide vaccine adjuvant
    • VO ID: VO_0000127
    • Description: 100 μl of 1.5% Al(OH)3 (Finke et al., 1990).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004191
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: PcrV
  • PcrV gene engineering:
    • Type: Recombinant protein preparation
    • Description: PcrV was produced as a lipopolysaccharide-free histidine-tagged infusion protein in pET16b and was purified by nickel chromatography (Holder et al., 2001).
    • Detailed Gene Information: Click Here.
  • Adjuvant: incomplete Freunds adjuvant
    • VO ID: VO_0000142
    • Description: 0.1 ml of incomplete Freund's adjuvant (Holder et al., 2001).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004674
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Attenuated Salmonella enterica serovar Typhimurium SL3261 expressing P. aeruginosa serogroup O11 O antigen (DiGiandomenico et al., 2004).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: Pathogen Free ICR
  • Vaccination Protocol: At 14-day intervals, groups of 30 mice were inoculated a total of three times in the abdomen via biolistic particle injection (Helios Gene Gun kit; Bio-Rad, Richmond, Calif.) on days 0, 14, and 28 with 2 μg of either pVR1020 (control) or pVR1020/oprF, which was used to coat 1-μm-diameter gold beads (Price et al., 2001).
  • Challenge Protocol: Two weeks after the final immunization, the mice were challenged with agar beads containing the P. aeruginosa FD immunotype 4 strain. The mice were first anesthetized with an intraperitoneal injection of sodium pentobarbital and then inoculated via a tracheal incision with 50 μl of an agar bead slurry encasing approximately 7 × 102 CFU of P. aeruginosa (Price et al., 2001).
  • Efficacy: A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen in immunized mice (Price et al., 2001).
  • Description: The immunoprotective potential of the pVR1020/oprF vaccine was tested in a mouse model of chronic pulmonary infection (Price et al., 2001).

Mouse Response

  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Monovalent DNA vaccination targeting OprF/OprI could protect 80% of mice 4 days p.i. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).

Mouse Response

  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: All mice vaccinated with multivalent DNA via imEPT survived for more than 10 days p.i. with PAK. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).

Mouse Response

  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Monovalent DNA vaccination targeting PcrV could protect 80% of mice 4 days p.i. On the other hand, 70% of mice immunized with the control plasmid, PilA vaccine, or multivalent vaccine via GG were dead within 5 days p.i. (p < 0.01) (Saha et al., 2006).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Female BALB/c mice, 12 to 16 weeks old, received 100 μl (27 ,ug) of OprI suspended in 100 μl of 1.5% Al(OH)3 intraperitoneally on days 0, 14, 35, and 63. Controls received Al(OH)3 only (Finke et al., 1990).
  • Challenge Protocol: mice were challenged intraperitoneally 10 days after the last immunization with 200 μl of a P. aeruginosa serogroup 6 suspension. Mice vaccinated with recombinant OprI received 6 x 106 to 1 x 108 living organisms each. (Finke et al., 1990).
  • Efficacy: Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa (Finke et al., 1990).

Mouse Response

  • Host Strain: CF-1
  • Vaccination Protocol: On day 0, groups of 10 female CF-1 mice weighing 22 to 25 g were immunized intramuscularly in the hind leg (10 μg of immunogen in 0.1 ml of incomplete Freund's adjuvant), followed by a booster dose (10 μg in saline) without adjuvant on day 14 (Holder et al., 2001).
  • Challenge Protocol: Using the burned mouse model, mice were challenged by one of three strains of P. aeruginosa (Holder et al., 2001).
  • Efficacy: Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls (Holder et al., 2001).

Mouse Response

  • Vaccination Protocol: For oral vaccination, mice were fed 100 μl of either PBS or the Salmonella vector and vaccine strains (1 × 109 to 5 × 109 CFU) by intragastric gavage. Oral inoculation was repeated once per week for a total of 4 weeks. For i.p. vaccination, mice were inoculated with a single dose of either PBS or each Salmonella strain (106 CFU) (DiGiandomenico et al., 2004).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged with P. aeruginosa strains 9882-80 (serogroup O11) and 6294 (serogroup O6) (DiGiandomenico et al., 2004).
  • Efficacy: Orally vaccinated mice with an O11 strain (9882-80) at 6 and 12 times the 50% lethal dose showed increased survival in mice that received the vaccine compared to phosphate-buffered saline (PBS)- and vector-treated controls; no difference in survival was seen with a heterologous strain, 6294 (serogroup O6). In addition, significant protection against 9882-80 was not observed in i.p. vaccinated animals (DiGiandomenico et al., 2004).
References References References References References References References
Price et al., 2001: Price BM, Galloway DR, Baker NR, Gilleland LB, Staczek J, Gilleland HE Jr. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infection and immunity. 2001; 69(5); 3510-3515. [PubMed: 11292786].
Saha et al., 2006: Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine. 2006; 24(37-39); 6240-6249. [PubMed: 16806598].
Saha et al., 2006: Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine. 2006; 24(37-39); 6240-6249. [PubMed: 16806598].
Saha et al., 2006: Saha S, Takeshita F, Sasaki S, Matsuda T, Tanaka T, Tozuka M, Takase K, Matsumoto T, Okuda K, Ishii N, Yamaguchi K, Klinman DM, Xin KQ, Okuda K. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine. 2006; 24(37-39); 6240-6249. [PubMed: 16806598].
Finke et al., 1990: Finke M, DuchĂȘne M, Eckhardt A, Domdey H, von Specht BU. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infection and immunity. 1990; 58(7); 2241-2244. [PubMed: 2114360].
Holder et al., 2001: Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infection and immunity. 2001; 69(9); 5908-5910. [PubMed: 11500471].